Eric J Jordan1, Charles Fiske2, Ronald J Zagoria1, Antonio C Westphalen3,4. 1. Department of Radiology & Biomedical Imaging, University of California San Francisco, 505 Parnasssus Ave. M-391, San Francisco, CA, 94143, USA. 2. RadNet Medical Imaging, Walnut Creek, CA, USA. 3. Department of Radiology & Biomedical Imaging, University of California San Francisco, 505 Parnasssus Ave. M-391, San Francisco, CA, 94143, USA. antonio.westphalen@ucsf.edu. 4. Department of Radiology & Biomedical Imaging and Urology, University of California San Francisco, San Francisco, CA, USA. antonio.westphalen@ucsf.edu.
Abstract
PURPOSE: To evaluate the utility of PI-RADS v2 to diagnose clinically significant prostate cancer (CS-PCa) with magnetic resonance ultrasound (MR/US) fusion-guided prostate biopsies in the non-academic setting. MATERIALS/ METHODS: Retrospective analysis of men whom underwent prostate multiparametric MRI and subsequent MR/US fusion biopsies at a single non-academic center from 11/2014 to 3/2016. Prostate MRIs were performed on a 3-Tesla scanner with a surface body coil. The Prostate Imaging Reporting and Data System (PI-RADS) v2 scoring algorithm was utilized and MR/US fusion biopsies were performed in selected cases. Mixed effect logistic regression analyses and receiver-operating characteristic (ROC) curves were performed on PI-RADS v2 alone and combined with PSA density (PSAD) to predict CS-PCa. RESULTS: 170 patients underwent prostate MRI with 282 PI-RADS lesions. MR/US fusion diagnosed 71 CS-PCa, 33 Gleason score 3+3, and 168 negative. PI-RADS v2 score is a statistically significant predictor of CS-PCa (P < 0.001). For each one-point increase in the overall PI-RADS v2 score, the odds of having CS-PCa increases by 4.2 (95% CI 2.2-8.3). The area under the ROC curve for PI-RADS v2 is 0.69 (95% CI 0.63-0.76) and for PI-RADS v2 + PSAD is 0.76 (95% CI 0.69-0.82), statistically higher than PI-RADS v2 alone (P < 0.001). The rate of CS-PCa was about twice higher in men with high PSAD (≥0.15) compared to men with low PSAD (<0.15) when a PI-RADS 4 or 5 lesion was detected (P = 0.005). CONCLUSION: PI-RADS v2 is a strong predictor of CS-PCa in the non-academic setting and can be further strengthened when utilized with PSA density.
PURPOSE: To evaluate the utility of PI-RADS v2 to diagnose clinically significant prostate cancer (CS-PCa) with magnetic resonance ultrasound (MR/US) fusion-guided prostate biopsies in the non-academic setting. MATERIALS/ METHODS: Retrospective analysis of men whom underwent prostate multiparametric MRI and subsequent MR/US fusion biopsies at a single non-academic center from 11/2014 to 3/2016. Prostate MRIs were performed on a 3-Tesla scanner with a surface body coil. The Prostate Imaging Reporting and Data System (PI-RADS) v2 scoring algorithm was utilized and MR/US fusion biopsies were performed in selected cases. Mixed effect logistic regression analyses and receiver-operating characteristic (ROC) curves were performed on PI-RADS v2 alone and combined with PSA density (PSAD) to predict CS-PCa. RESULTS: 170 patients underwent prostate MRI with 282 PI-RADS lesions. MR/US fusion diagnosed 71 CS-PCa, 33 Gleason score 3+3, and 168 negative. PI-RADS v2 score is a statistically significant predictor of CS-PCa (P < 0.001). For each one-point increase in the overall PI-RADS v2 score, the odds of having CS-PCa increases by 4.2 (95% CI 2.2-8.3). The area under the ROC curve for PI-RADS v2 is 0.69 (95% CI 0.63-0.76) and for PI-RADS v2 + PSAD is 0.76 (95% CI 0.69-0.82), statistically higher than PI-RADS v2 alone (P < 0.001). The rate of CS-PCa was about twice higher in men with high PSAD (≥0.15) compared to men with low PSAD (<0.15) when a PI-RADS 4 or 5 lesion was detected (P = 0.005). CONCLUSION: PI-RADS v2 is a strong predictor of CS-PCa in the non-academic setting and can be further strengthened when utilized with PSA density.
Authors: Borna K Barth; Niels J Rupp; Alexander Cornelius; Daniel Nanz; Rainer Grobholz; Martin Schmidtpeter; Peter J Wild; Daniel Eberli; Olivio F Donati Journal: Curr Urol Date: 2019-03-08
Authors: Akshay Wadera; Mostafa Alabousi; Alex Pozdnyakov; Mohammed Kashif Al-Ghita; Ali Jafri; Matthew Df McInnes; Nicola Schieda; Christian B van der Pol; Jean-Paul Salameh; Lucy Samoilov; Kaela Gusenbauer; Abdullah Alabousi Journal: Br J Radiol Date: 2020-10-22 Impact factor: 3.039
Authors: Antonio C Westphalen; Farhad Fazel; Hao Nguyen; Miguel Cabarrus; Katryana Hanley-Knutson; Katsuto Shinohara; Peter R Carroll Journal: Int Braz J Urol Date: 2019 Jul-Aug Impact factor: 1.541
Authors: Nathan Velarde; Antonio C Westphalen; Hao G Nguyen; John Neuhaus; Katsuto Shinohara; Jeffry P Simko; Peder E Larson; Kirti Magudia Journal: Abdom Radiol (NY) Date: 2022-01-07
Authors: Yin Lei; Tian Jie Li; Peng Gu; Yu Kun Yang; Lei Zhao; Chao Gao; Juan Hu; Xiao Dong Liu Journal: Front Oncol Date: 2022-09-23 Impact factor: 5.738